The KPNA5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population providing a loss-of-function model for the KPNA5 gene in the A-549 human lung adenocarcinoma epithelial cell line. This product enables investigation of the nuclear transport receptor importin alpha-5, which recognizes classical nuclear localization signals (NLS). The polyclonal knockout background is generated via CRISPR/Cas9-mediated gene disruption, offering a heterogeneous population suitable for pooled functional analyses.
The A-549 cell line, derived from a 58-year-old Caucasian male with lung adenocarcinoma, exhibits adherent epithelial morphology and serves as a widely used cancer model. Its well-defined characteristics make it an ideal substrate for dissecting molecular mechanisms underlying lung tumorigenesis, drug sensitivity, and signaling pathway dynamics.
KPNA5 is an importin alpha adaptor that drives nuclear import of NLS-containing cargoes, forming a complex with importin beta (KPNB1) to dock at the nuclear pore via nucleoporins like NUP50 and NUP62. The Ran GTPase cycle, involving RCC1, RanBP1, RanGAP1, and NTF2, powers translocation, after which CAS (CSE1L) recycles KPNA5. This pathway mediates nuclear entry of transcription factors such as NF-??B, STAT3, and p53, thereby governing cell cycle progression, apoptosis, and stress responses. Additionally, KPNA5 participates in mitotic spindle assembly and facilitates viral nuclear import, exemplified by the influenza nucleoprotein (NP). Upstream, KPNA5 expression and activity are modulated by mitogenic signaling and the cell cycle machinery, with oncogenic STAT3 acting as both a regulator and cargo.
In the A-549 lung adenocarcinoma background, KPNA5 disruption allows dissection of how aberrant nucleocytoplasmic trafficking influences cancer cell behavior. Knockout may mislocalize key NLS-bearing regulators, affecting proliferation, survival, and viral susceptibility. This model thus facilitates studies of transport-dependent oncogenic signaling and viral replication mechanisms in a clinically relevant epithelial cancer context.
This knockout cell product supports diverse experimental approaches. Western blotting and RT-qPCR confirm KPNA5 expression loss, while immunofluorescence using GFP-NLS reporters quantifies nuclear import efficiency. Functional impacts can be assessed via proliferation (BrdU), viability (MTT), and cell cycle flow cytometry. Co-immunoprecipitation maps altered import complex interactions, and viral replication assays test influenza NP trafficking. Additionally, these cells can be used in drug transport studies to evaluate the role of KPNA5 in chemotherapeutic agent nuclear delivery. For technical information, please contact Ascent Research.
